The third webinar in ASH’s free, five-part series on the 2017 ASH Meeting on Hematologic Malignancies (MHM) will feature a discussion on the state of myelodysplastic syndromes (MDS) with three renowned clinicians in the area of MDS. The webinar will focus on how clinical practice has evolved in recent years, important conclusions from last year’s meeting, and what to expect at the meeting in September.

At the end of the webinar, participants will be able to submit questions during a Q&A session.

David Steensma, MD
Dana-Farber Cancer Institute, Cambridge, MA
2017 MHM Program Planning Committee Member

Bart Scott, MD
Fred Hutchinson Cancer Research Center, Seattle, WA
2017 MHM Program Speaker

Amy DeZern, MD
Johns Hopkins University, Baltimore, MD
2017 MHM Program Speaker


Register Here

IPSS-R MDS Risk Assessment Calculator

Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment Calculator


Click here

MDS Fact Sheet

MDS Factsheet for GPs General Practicioners

MDS Fact Sheet

Click here

Varicella Vaccine in MDS

Urgent Clarification on varicella vaccine policy

Current advice from the UK MDS Forum is not to give the Live Varicella Vaccine to patients with MDS.

Please read below correspondence between Professor Salisbury and Dr George Follows, the latter on behalf of the CLL Forum, on the varicella vaccine policy.
This is an external link to the British Society for Haematology  Click here

NICE Guideline

Lenalidomide for treating myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality.

NICE logo

Click here

BSH Guidelines

This is an external link to the home of the British Society for Haematology (BSH). 

BSH Logo Strapline RGB

Click here